Advertisement

Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts

  • Wei-Dong Jia
  • Ge-Liang Xu
  • Rong-Nan Xu
  • Hui-Chuan Sun
  • Lu Wang
  • Ji-Hai Yu
  • Jian Wang
  • Jian-Sheng Li
  • Zhi-Ming Zhai
  • Qiong Xue
Original Paper

Abstract

Purpose

To investigate the effect of octreotide on angiogenesis induced by human hepatocellular carcinoma (HCC) and to evaluate whether octreotide can suppress tumor growth in nude mice bearing human HCC xenografts through inhibition of angiogenesis.

Methods

Using MTT assay, invasion assay, migration assay, and Matrigel assay, the effects of octreotide on endothelial cells stimulated by vascular endothelial growth factor (VEGF) were evaluated in vitro. MTT assay was also used to investigate the effects of octreotide on human HCC cells with high (MHCC97-H) and low (MHCC97-L) metastatic potential that were established from the animal model of human HCC LCI-D20 in nude mice. The expression of somatostatin receptor (SSTR) subtypes in human umbilical vein endothelial cells (HUVECs), MHCC97-H, and MHCC97-L cells was detected by RT-PCR analysis. An LCI-D20 corneal micropocket model in nude mice was used to evaluate the effect of octreotide on angiogenesis induced by human HCC in vivo. Male nude mice were subcutaneously implanted with LCI-D20 tumor tissues for the tumor xenograft studies. Microvessel density was analyzed in CD34-stained tumor sections by the immunohistochemical SP method.

Results

In vitro, octreotide inhibited the proliferation, invasion, and differentiation of HUVECs elicited by VEGF. RT-PCR analysis demonstrated that HUVECs expressed the somatostatin receptor subtype SSTR3. In vivo, octreotide was sufficiently potent to suppress nude mice corneal neovascularization induced by tumor tissues from LCI-D20. Systemic administrations of octreotide produced a significant suppression of the growth of LCI-D20. In cell culture, MHCC97-H and MHCC97-L cells were insensitive to octreotide at concentrations that significantly inhibited endothelial cells proliferation. The HCC cells used did not express any known SSTRs. Immunohistochemical studies of tumor tissues revealed decreased microvessel density in octreotide-treated animals as compared with controls.

Conclusions

The present study demonstrates that the somatostatin analogue octreotide is a potent antitumor angiogenesis compound and the antiproliferative effect of octreotide on tumor growth in nude mice bearing HCC xenografts may be mediated, at least in part, by its suppressive effect on blood vessel supply. The somatostatin analogue octreotide might provide a useful and relatively nontoxic adjuvant therapy in the treatment of HCC.

Keywords

Hepatocellular carcinoma Neovascularization Octreotide Endothelial cells 

References

  1. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan DM, Schettini G (1999) Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 13:647–655PubMedGoogle Scholar
  2. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407PubMedGoogle Scholar
  3. Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, Agostinelli R, Muretto P, Catalano G (2001) Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 19:8–12CrossRefPubMedGoogle Scholar
  4. Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM (2000) Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 278:H1815–1822PubMedGoogle Scholar
  5. Danesi R, Del Tacca M (1996) The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 45:49–50Google Scholar
  6. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD (1997) Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201–995). Clin Cancer Res 3:265–272PubMedGoogle Scholar
  7. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Markidou S, Panagiotakos D, Chrysohoou C, Bazinis A, Paraskevas E (2002) The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245–1250PubMedGoogle Scholar
  8. Evers BM, Parekh D, Townsend CM Jr, Thompson JC (1991) Somatostatin and analogues in the treatment of cancer (review). Ann Surg 213:190–198PubMedGoogle Scholar
  9. Florio T, Schettini G (1996) Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors (review). J Mol Endocrinol 17:89–100PubMedGoogle Scholar
  10. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6Google Scholar
  11. Folkman J (1996) Fighting cancer by attacking its blood supply. Sci Am. 275:150–154Google Scholar
  12. Gorrin-Rivas MJ, Arii S, Mori A, Takeda Y, Mizumoto M, Furutani M, Imamura M (2000) Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg 231:67–73PubMedGoogle Scholar
  13. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK (1989) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933–943PubMedGoogle Scholar
  14. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMedGoogle Scholar
  15. Higgins RD, Yan Y, Schrier BK (2002) Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 74:553–559CrossRefGoogle Scholar
  16. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 52:2745–2756Google Scholar
  17. Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y (2002) Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 65:200–206CrossRefPubMedGoogle Scholar
  18. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 42:442–447PubMedGoogle Scholar
  19. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide (review). N Engl J Med 334:246–254CrossRefPubMedGoogle Scholar
  20. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J (2000) Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 268:567–571CrossRefPubMedGoogle Scholar
  21. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA (1992) Requirement of the integrin ß3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117:1101–1107.PubMedGoogle Scholar
  22. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7:630–636PubMedGoogle Scholar
  23. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858–863CrossRefPubMedGoogle Scholar
  24. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92:545–550CrossRefPubMedGoogle Scholar
  25. Nakashio A, Fujita N, Tsuruo T (2002) Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer 98:36–41CrossRefPubMedGoogle Scholar
  26. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK (2001) Microvessel density, vascular endothelial growth factor, and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838–845PubMedGoogle Scholar
  27. Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606.PubMedGoogle Scholar
  28. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA (1994) Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116:1148–1152PubMedGoogle Scholar
  29. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA (2000) Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23:319–321CrossRefPubMedGoogle Scholar
  30. Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann WH (2002) Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 40:395–400CrossRefPubMedGoogle Scholar
  31. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A (2000) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157:1703–1711PubMedGoogle Scholar
  32. Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, Ma ZC (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239–243CrossRefPubMedGoogle Scholar
  33. Sun HC, Li XM, Xue Q, Chen J, Gao DM, Tang ZY (1999) Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice. World J Gastroenterol 5:116–118PubMedGoogle Scholar
  34. Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K (2002) Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 35:861–867CrossRefPubMedGoogle Scholar
  35. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81:814–821PubMedGoogle Scholar
  36. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L (2001) Angiomotin: an angiostatin binding protein that regulates endothelial cell an migration and tube formation. J Cell Biol 152:1247–1254CrossRefPubMedGoogle Scholar
  37. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581–586PubMedGoogle Scholar
  38. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL (2000) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43–48PubMedGoogle Scholar
  39. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J (1991) Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245–251PubMedGoogle Scholar
  40. Xu GL, Yi SH, Xu RN (2001) Effects of octreotide on implanted liver tumor after partial hepatectomy in rats. Chin J Surg 39:948–950Google Scholar
  41. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68–77Google Scholar
  42. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94:2036–2044PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Wei-Dong Jia
    • 1
  • Ge-Liang Xu
    • 1
  • Rong-Nan Xu
    • 1
  • Hui-Chuan Sun
    • 2
  • Lu Wang
    • 2
  • Ji-Hai Yu
    • 1
  • Jian Wang
    • 3
  • Jian-Sheng Li
    • 1
  • Zhi-Ming Zhai
    • 3
  • Qiong Xue
    • 2
  1. 1.Department of General SurgeryAnhui Provincial HospitalHefeiP.R. China
  2. 2.Liver Cancer InstituteZhongshan HospitalShanghaiP.R. China
  3. 3.Department of Central LaboratoryAnhui Provincial HospitalHefeiChina

Personalised recommendations